Literature DB >> 1969262

Responses to sulfur dioxide and exercise by medication-dependent asthmatics: effect of varying medication levels.

W S Linn1, D A Shamoo, R C Peng, K W Clark, E L Avol, J D Hackney.   

Abstract

Twenty-one volunteers with moderate to severe asthma were exposed to sulfur dioxide (SO2) at concentrations of 0 (control), 0.3, and 0.6 ppm in each of three medication states: (1) low (much of their usual asthma medication withheld), (2) normal (each subject on his own usual medication schedule), and (3) high (usual medication supplemented by inhaled metaproterenol before exposure). Theophylline, the medication usually taken by subjects, was often supplemented by beta-adrenergics. Exposures were for 10 min and were accompanied by continuous heavy exercise (ventilation approximately 50 l/min). Lung function and symptoms were measured before and after exposure. With normal medication, symptomatic bronchoconstriction occurred with exercise and was exacerbated by 0.6 ppm SO2, as reported for mildly unmedicated asthmatics studied previously. Both baseline and post-exposure lung function were noticeably worse in the low-medication state. High medication improved baseline lung function and prevented most bronchoconstrictive effects of SO2/exercise. High medication also increased heart rate and apparently induced tremor or nervousness in some individuals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969262     DOI: 10.1080/00039896.1990.9935920

Source DB:  PubMed          Journal:  Arch Environ Health        ISSN: 0003-9896


  2 in total

1.  Medication use modifies the health effects of particulate sulfate air pollution in children with asthma.

Authors:  A Peters; D W Dockery; J Heinrich; H E Wichmann
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

Review 2.  Evaluation of the experimental basis for assessment factors to protect individuals with asthma from health effects during short-term exposure to airborne chemicals.

Authors:  Mia K V Johansson; Gunnar Johanson; Mattias Öberg
Journal:  Crit Rev Toxicol       Date:  2015-10-29       Impact factor: 5.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.